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Effect of Intraoperative Dexmedetomidine Infusion on Perioperative

Opioid Use
Background: A 71-year-old female patient presented for robotic right hemicolectomy. The
patient had a history of colon cancer, hypertension, and allergies to penicillin and propofol. The
decision was made to approach the anesthetic plan with Enhanced Recovery After Surgery
(ERAS) protocols in place. These protocols are intended to decrease or eliminate opioids, guide
goal-directed fluid management, and speed recovery after surgery. Dexmedetomidine infusion
was added as an adjunct to this protocol, and the patient was followed to assess opioid
consumption post-operatively.
Purpose: To evaluate current data related to dexmedetomidine infusion to make evidence-based
recommendations on the use of the drug for perioperative purposes.
Process: A systematic literature review was carried out using the University of North Dakota’s
Library of the Health Sciences. Databases used include Cochrane, PubMed, and searches of CDC
statistics. The search was conducted using key words and publication date limits to include
recent and applicable data. Literature was synthesized to develop recommendations for an
evidence-based approach to use of perioperative dexmedetomidine.
Results: Randomized control trials, systematic reviews, and case reports were included in the
final synthesis of literature. The literature suggests that dexmedetomidine may be used as part of
an opioid-sparing anesthetic technique. Some of the strongest evidence advocates for a
dexmedetomidine/opioid PCA post-operatively to decrease post-operative opioid consumption.
Implications: ERAS protocols are well-established as methods to increase patient satisfaction,
decrease opioid consumption, and improve patient outcomes. Higher quality future research is
needed to determine if dexmedetomidine should be used as an analgesic adjunct. Initial studies
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suggest that dexmedetomidine infusion is a viable adjunct for opioid-sparing anesthetic
techniques.
Keywords: Dexmedetomidine, ERAS, opioid-sparing, pain
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EFFECT OF INTRAOPERATIVE DEXMEDETOMIDINE INFUSION ON
PERIOPERATIVE OPIOID USE
Background
Epidemiologic data presented by the Center for Disease Control and Prevention (CDC)
reports that in 2015, there were 174.6 per 100,000 non-fatal drug-related overdoses brought to
Emergency Rooms (ERs) in the United States. Of these, opioids had the highest incidence,
followed by heroin, methadone, and “other opioids”, with all of these making up just over 50%
of the total ER visits. Similarly, the CDC reported that 42,249 opioid-related overdose deaths
occurred in 2016, which accounted for 66% of all drug-related deaths. What complicates this,
and leads to great concern within the medical community, is that over 14,000 of those deaths
(and possibly more) can be traced back to prescription opioids (CDC, 2018). Opioids are often
prescribed to control post-operative pain.
Opioids have been a reliable and effective form of perioperative pain control for
hundreds of years, stemming from the historical use of the opium poppy. While effective, they
do come with an undesirable array of side effects including nausea, vomiting, constipation,
urinary retention, respiratory depression, and dependence (Nagelhout & Elisha, 2018). A recent
study demonstrated that interventions anesthesia professionals utilized intraoperatively had the
potential to decrease the opioid requirement post-operatively, even in those who are already
opioid-dependent prior to surgery (Nielsen, Fomsgaard, Nikolajsen, Dahl, and Mathiesen, 2018).
Opioids have been considered a primary analgesic in the practice of anesthesia due to
both their efficacy in pain management and their low cost. This current opioid epidemic in the
United States has created a unique situation for patients in the perioperative realm. Because the
need exists for adequate intraoperative and post-operative pain control, anesthesia professionals
must continue to consider opioid alternatives for analgesia. Enhanced recovery after surgery
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(ERAS) protocols have begun to shape the way that anesthesia professionals approach their
analgesic plans. In this paper, the author described current ERAS methods and sought to
determine if there is a place for dexmedetomidine infusions within these protocols. Because of
this, the author chose to research the question “In patients having outpatient surgery, does
perioperative use of intravenous dexmedetomidine versus traditional opioid anesthesia produce
decreased perioperative use of opioids?”
Case Report
A 71-year-old, 165 cm, 120 kg female patient presented for a robotic right
hemicolectomy. Her past medical history included asthma, hypertension and LVEF of 55%,
GERD, colon cancer, morbid obesity, and arthritis. Past surgical history included previous
sigmoidectomy for colon cancer, as well as colonoscopy and esophagoduodenoscopy. Home
medications included baby aspirin, losartan-hydrochlorothizide, multivitamin, and albuterol
inhaler. She had drug allergies to penicillin, ketorolac, and propofol. Pre-anesthetic evaluation
revealed history of post-operative nausea and vomiting, as well as history of difficult intubation.
Airway evaluation showed a Mallampati score of 2, temporomandibular distance of greater than
3 fingerbreadths, full neck range of motion, and intact dentition. Baseline vital signs were within
normal limits. The patient was classified as an ASA Physical Status 3. An l8-gauge IV was
started in the preoperative holding room with LR infusing by gravity.
The patient was given midazolam 2 mg and taken back to the operating room. She was
transferred to the operating room table and standard noninvasive monitors were attached along
with bispectral index monitoring. The patient was preoxygenated with 15 liters per minute 100%
O2 by mask. General anesthesia was induced with etomidate 12 mg, ketamine 30 mg, fentanyl
100 mcg, lidocaine 50 mg, and rocuronium 50 mg. The patient was successfully intubated on the
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first attempt with a Macintosh 3 blade (Grade II Cormack-Lehane view), 7.0 endotracheal tube
with stylet. Endotracheal tube placement was confirmed with EtCO 2 and bilateral breath sounds
were auscultated. The tube was secured with tape, sevoflurane was initiated at ½ MAC, and fresh
gas flows were decreased to O2 0.5 L/min and air 0.5 L/min. Magnesium 3g was bolused over 30
minutes, and dexmedetomidine 0.5-0.7 mcg/kg/hr infusion was initiated along with lidocaine
infusion at 1 mg/kg/hr LBW (60 mg/hr).
Clindamycin 900 mg and Metronidazole 500 mg were initiated after induction, and
dexamethasone 8 mg and ondansetron 4 mg were administered for PONV prophylaxis. Vital
signs remained within normal limits throughout the case with the use of a phenylephrine
infusion, as well as 25 mg total of ephedrine. Intravenous fluids totaled 1,600 ml with 180 ml of
urine output, and an estimated blood loss of 50 ml. Per the facility’s ERAS protocol, ketamine 30
mg was administered each hour throughout the case for a total of 120 mg. The patient was
reversed with sugammadex 300 mg. An awake extubation was performed, with the patient
stating comfort upon arrival to the post-anesthesia care unit. No narcotic medications were given
in the immediate post-operative period.
Post-operative pain control was discussed with the surgeon, and an agreement was made
to put the patient on scheduled acetaminophen and gabapentin postoperatively with oxycodoneacetaminophen tablets for breakthrough pain. Within 24 hours postoperatively, the patient had
received only two narcotic doses for breakthrough pain.
Methods
A search of the current literature was performed on several resource databases through
the University of North Dakota Health Sciences Library, including PubMed, ClincalKey, and
Cochrane. Each search was limited to include articles in the English language less than five years
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old, and studies related the adult human population (19+ years of age). These limits were chosen
to obtain relevant, recent data on adult patients. MeSH keywords such as dexmedetomidine,
analgesia, postoperative, opioid, anesthesia, opioid free, multimodal, and postoperative opioids
were used. The date limits were increased to include all articles 15 years or newer related to
“intravenous dexmedetomidine analgesia” due to lack of recent evidence specific to the
intravenous route of administration.
Cochrane database was searched to find Cochrane reviews and trials related to opioidfree anesthesia using the search terms opioid AND free AND anesthesia, as well as
dexmedetomidine AND analgesia. During this search, only 7 Cochrane reviews were returned,
only one of which was relevant to the current topic of decreasing post-operative opioid use.
Alternative websites were searched, including the American Association of Nurse
Anesthetists website for position statements on opioid prescribing, the use of intraoperative and
post-operative opioids, and opioid-free anesthesia. The United States Centers for Disease Control
and Prevention website was searched for position statements on the opioid crisis, as well as
epidemiologic data regarding drug poisonings and overdoses. Information was also found in a
recently revised anesthesia textbook. Three total sources have been used outside of PubMed.
Discussion
Enhanced Recovery After Surgery
Enhanced recovery after surgery, or ERAS, is a growing movement of improving patient
outcomes and shortening hospital stays through judicious use of pharmaceuticals and patient care
techniques. As anesthesia professionals, one of the main roles that we play in ERAS involves the
use of multimodal analgesia (MMA) intraoperatively. Multimodal analgesia means the use of
non-opioid analgesics, as well as balanced use of opioids, to achieve perioperative pain control.
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Lavand’homme and Estebe (2018) discussed undesirable side effects of opioid analgesia,
including opioid-induced hyperalgesia, post-operative nausea and vomiting, constipation, ileus,
and dependence. According to these authors, the side effects of opioids can lead to long-term
chronic pain, as well as prolonged hospital stay.
Reagan, O’Sullivan, Gannon, and Steinberg (2017) explored the role of an opioid-free
anesthetic (OFA) in post-operative opioid use for patients undergoing reconstructive pelvic
surgery. In the randomized control study of 138 participants, MMA and opioid-sparing methods
were found to provide equivalent pain control while decreasing post-operative opioid
requirements. McLaughlin et al. (2018) found similar results when they paired multimodal
analgesia with patients undergoing shoulder arthroplasty. Their prospective cohort study
involved two groups of 75 participants each: one who received standard opioid anesthesia, and
one who received a multimodal regimen. The multimodal group had lower pain scores on postoperative day 0,1, and 2 (P < .01), as well as shorter hospital stays (P < .01), and had no more
complications than traditional opioid analgesia. The shorter hospitalization described by
McLaughlin et al. (2018) also provided for an average of $1,000 USD less in overall hospital
costs for patients undergoing MMA. While the figure was not found to be statistically
significant, it stands to reason that the average patient may consider this a benefit.
So, what exactly is MMA? According to Brown, Pavone, and Naranjo (2018), this
technique involves administering different drugs (with different mechanisms of action) together
to achieve the anesthetized state. By doing this, the amount of each individual drug given is
decreased versus a technique which uses only one or very few different agents. In the same way
that a state of surgical anesthesia can be achieved with a multimodal approach, so can analgesia
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during the perioperative period. To accomplish this, we must both define pain and understand the
methods of pain transduction.
Brown et al. (2018) made a clear distinction between the definition of pain and
nociception. Pain is considered a conscious perception of painful stimuli whose severity depends
on patient perception. This definition, while broad, is in congruence with the well-known
definition saying that pain is “whatever the patient says it is.” Nociception is the actual
transmission of painful stimulus within the nervous system. While nociception is sometimes
what causes patients to perceive pain, it also can cause hemodynamic and humoral response
changes such as hypertension, tachycardia, and cortisol release, even while patients are in the
anesthetized state.
Mechanisms of Pain Modulation
Clarke et al. (2012) stated that pain can be classified as acute (less than 3 months
duration) or chronic (lasting greater than 3-6 months). The cause of acute pain is generally
known, which is what separates it from chronic pain, and these authors highlight the new
knowledge that poorly treated surgical pain can be a precursor to chronic pain. Chronic postsurgical pain can be prevented with a multimodal approach using neuraxial techniques,
peripheral regional techniques, and drugs with multiple mechanisms of action. Ideally, pain
management would be proactive, or anticipatory.
Clarke et al. (2012) state that somatic and visceral pain are well-controlled by opioid
analgesics, while neuropathic pain may be better treated by more unconventional pain
medications such as antidepressants, gabapentinoids, muscle relaxants, and intravenous infusions
such as lidocaine, ketamine, and dexmedetomidine.
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Not all types of pain respond to the same pain medications. Lavond’homme and Estebe
(2018) highlighted the multiple pathways and causes of nociception, including glutamate (fast
onset, sharp pain), substance P (a peptide found in and released from peripheral afferent
nociceptor C fibers), bradykinin, histamine, serotonin (5-HT), and prostaglandins among others,
and discuss multimodal analgesic agents that may enhance both intraoperative and post-operative
pain (Nagelhout & Elisha, 2018). With so many modes of pain transmission, it is important to
note that the opioid pathway is only one of many that may be modulated to manage pain.
Non-Opioid Analgesic Methods
Ketamine. Ketamine is a phencyclidine that produces analgesia through antagonism of
the N-methyl-D-aspartate (NMDA) receptor, as well as inhibition of mu, delta, and kappa opioid
receptors. This drug generally provides analgesia and anesthesia without loss of respiratory
reflexes (Nagelhout & Elisha, 2018). Aronsohn et al. (2018) wrote a case report on intraoperative
use of ketamine to enhance analgesia for a morbidly obese patient (BMI 50.1 kg/m 2) undergoing
a laparoscopic gastric sleeve procedure. The patient presented for surgery with a history of
obstructive sleep apnea (OSA), non-compliant with her CPAP. With the goal of avoiding adverse
respiratory events related to narcotics, the authors used ketamine as part of an opioid-free total
intravenous anesthesia protocol. The case proceeded with a ketamine loading dose of 5 mg/kg
and a maintenance infusion of 5 mcg/kg/min. This case report states that the patient had
comparable analgesia to an opioid technique, but had no episodes of apnea, hypoxia (SpO2 <
93%), or airway obstruction in the PACU. In addition to meeting outcomes for respiratory
function, the patient was also ambulating unassisted at 90 minutes post-op.
There is evidence to show that intraoperative use of ketamine infusions is helpful for pain
control, even in patients with chronic pain and opioid use. A randomized, double-blind study of
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147 patients by Nielsen, Fomsgaard, Nikolajsen, Dahl, and Mathiesen (2018) showed that
patients with chronic opioid-dependent pain undergoing spinal fusion have decreased use of
opioids one year from surgery and have higher workforce association when intraoperative
ketamine is used. While this does not relate immediately to postoperative or intraoperative
analgesia, it shows that our nation’s opioid crisis can be combated partially by what anesthesia
professionals do intraoperatively.
Lidocaine. Boysen, Pappas, and Evans (2018) wrote a case comparison of two patients
undergoing general anesthesia, one for bariatric surgery and one for endoscopic retrograde
cholangiopancreatogram (ERCP). Both patients were administered intraoperative infusions of
lidocaine and dexmedetomidine for pain control and sedation. As with many of the other studies,
analgesics including subanesthetic doses of ketamine, as well as intravenous acetaminophen and
ketorolac were used to maintain analgesia, and both patients were discharged having received no
narcotics (Boysen, Pappas, & Evans, 2018). These examples, while few, are evidentiary to the
possibility of a fully opioid-free anesthetic option, even for major surgeries such as bariatrics.
Opioid-free analgesia can be achieved with modes such as these, in addition to administration of
dexamethasone, selective cyclooxygenase-2 inhibitors such as celecoxib, and intravenous
NSAIDS such as ketorolac can offer equivalent analgesia with potentially fewer undesirable side
effects (Barazanchi, MacFater, Rahiri, Tutone, Hill, & Joshi, 2018).
Dexmedetomidine. Intraoperative infusions of dexmedetomidine have become an area of
interest for anesthetists looking to decrease perioperative narcotic administration. A prospective,
randomized, double-blind trial by Bakan et al. (2015) explored the use of dexmedetomidine
infusions in patients undergoing laparoscopic cholecystectomy. Eighty patients of physical status
I-II were allocated into two groups, one opioid free with propofol, dexmedetomidine, and
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lidocaine infusions, and one with remifentanil and propofol infusions. These authors found that
while dexmedetomidine can result in slower waking times, it is also associated with significantly
lower pain scores, fewer rescue analgesic, and fewer rescue anti-emetics.
One of the most promising areas of research involves perioperative administration of
dexmedetomidine, whether within intrathecal mixtures, nerve block mixtures, or as part of an
intravenous anesthetic and analgesic cocktail. For the purposes of this case report, the
intravenous method will receive primary focus as part of the MMA technique.
Mechanism of action. Dexmedetomidine is a relatively selective alpha-2 agonist whose
anti-nociceptive effects can be explained by stimulation of alpha-2 adrenoreceptors in the brain
(locus coeruleus) and spinal cord, as well as hyperpolarization of interneurons and reduction of
substance P and glutamate. The analgesic effect has been shown to be minimal at doses intended
for light sedation. However, Weerink et al. (2017) found that the opioid-sparing effect stemming
from altered perception and reduced anxiety may still be beneficial. Dexmedetomidine has the
added benefit of providing sedative, anxiolytic, and antiemetic properties, even more so than its
less-selective alpha-2 agonist relative, clonidine (Blaudszun et al., 2012).
Dexmedetomidine is rapidly distributed, with an initial distribution half-life of 6 minutes
and a terminal elimination half-life of 2 hours. It is metabolized into only inactive metabolites
and excreted primarily through hepatic and renal modalities. Because of this, the initial dose of
dexmedetomidine should be decreased in patients with chronic hepatic or renal insufficiency, or
those at risk for developing these conditions (Nagelhout & Elisha, 2018).
According to Weerink et al. (2017), dexmedetomidine hydrochloride is generally diluted
to a concentration of 4 mcg/ml or 8 mcg/ml prior to infusion. The drug comes in two brand
names; Dexdor and Precedex. Dexdor’s instructions state to start at an initial infusion rate of 0.7
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mcg/kg/hr with no loading dose, and titrate to effect with dose range 0.2-1.4 mcg/kg/hr.
Precedex’s instructions state to begin with a loading dose of 1 mcg/kg over 10 minutes, and
follow with maintenance infusion of 0.2-0.7 mcg/kg/hr. Procedural sedation allows the same
loading dose of 1 mcg/kg over 10 minutes, with dose range 0.2-1 mcg/kg/hr.
Dexmedetomidine is FDA approved for intravenous use for up to 24 hours. It is highly
protein-bound, with 94% bound to albumin and alpha-1-glycoprotein in plasma. It easily crosses
the blood-brain barrier and placenta, and the apparent volume of distribution is related to body
weight. Ingrande and Lemmens (2010) discussed that dosing in the morbidly obese should often
be based on lean body weight, but there are no specific recommendations for dosing
dexmedetomidine infusions. Dexmedetomidine undergoes an extensive first-pass effect when
given orally, leaving only 16% bioavailable. Intranasally, it is well-absorbed (Weerink et al.,
2017).
Adverse effects. Coadministration of dexmedetomidine in addition to other anesthetic
modalities such as propofol, inhaled agents, and opioids can lead to compounding hemodynamic
effects including bradycardia and hypotension. A balanced technique should be used to avoid
these potential adverse effects.
Preoperative Applications
Pasin et al. (2015) provided a meta-analysis of dexmedetomidine versus midazolam for
preoperative sedation in pediatrics. While this paper focuses on adult patients, it is worth noting
that the authors noted the pediatric patients had significantly decreased anxiety on separation
from the parents, decreased postoperative agitation, and more effective postoperative analgesia
compared to midazolam. It should also be noted that the use of dexmedetomidine in pediatric
patients is not FDA approved, and more research is required to gain approval for this use.
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According to Weerink et al. (2017), preoperative sedation can be achieved in pediatric
patients and uncooperative elderly patients by means of intranasal dexmedetomidine. While this
is not currently an FDA-approved method of administration for the drug, it has been shown to be
effective due to bioavailability of the drug through mucosal membranes. More research would
need to be done to determine dexmedetomidine’s usefulness in this way, and to determine
whether this also has opioid-sparing effect.
Naaz and Ozair (2014) described a dosing regimen in their review of dexmedetomidine in
practice. According to this review, a dose of dexmedetomidine 0.33-0.67 mcg/kg IV or 2.5
mcg/kg IM may be given 15 minutes preoperatively for sedation and reduction of oxygen
consumption.
Intraoperative Applications
The subject of this case report was administered dexmedetomidine 0.5-0.7 mcg/kg/hr
intraoperatively. While there are preoperative and postoperative indications for use of
dexmedetomidine, the protocols at this hospital allowed only for intraoperative infusion. As
stated previously, dexmedetomidine was used as an adjunct along with lidocaine 1 mg/min IV, as
well as magnesium and ketamine boluses.
A meta-analysis by Singh et al. (2017) explored the role of intraoperative
dexmedetomidine infusion for 24-hour post-operative analgesic requirements in obese patients
undergoing bariatric surgery. The authors found that both intraoperative and postoperative
infusions of dexmedetomidine resulted in an opioid-sparing effect in early and extended
postoperative courses. These morbidly obese patient had not only improved pain control, but
they also benefitted from lower incidence of postoperative nausea and vomiting than their
placebo counterparts (Singh et al., 2017).
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Another study by Bielka, Kuchyn, Babych, Martycschenko, and Inozemtsev (2018)
discussed the use of dexmedetomidine infusion of 0.5 mcg/kg/hr vs saline placebo from
induction of anesthesia until extubation in a group of physical status 1-2 patients undergoing
laparoscopic cholecystectomy. These authors found that patients had lower incidence of
postoperative pain, longer time to first use of rescue analgesia, and an overall decrease in
postoperative opioid consumption.
During cervical spine cases, it is imperative that the patient have an adequate airway for
extubation, which can often mean careful titration of narcotics. Gandhi et al. (2017) conducted a
randomized controlled trial of 60 patients, split into two groups. One received a
dexmedetomidine loading dose of 1 mcg/kg over 10 minutes, followed by an intraoperative
infusion of 0.5 mcg/kg/hr, followed by a reduced infusion of 0.2 mcg/kg/hr for 24 hours
postoperatively. The second group received a volume matched bolus and infusion of saline. The
authors found that the dexmedetomidine regimen decreased anesthetic requirement
intraoperatively and provided effective analgesia postoperatively (Gandhi et al., 2017).
While there are studies looking at adding dexmedetomidine to regional anesthesia to
prolong the duration of peripheral nerve blocks, some studies have shown that an intravenous
bolus of the drug may also prolong block duration. Kang et al. (2018) conducted a prospective,
double-blind, randomized controlled trial of 72 patients. The goal of the study was to determine
first pain at surgical site in patients having interscalene block (ISB) for shoulder surgery. Each
patient received an ISB with 15 ml 0.5% ropivacaine, and then four groups (n = 18 in each) were
assigned to receive a 50 ml bolus over 30 minutes of either saline placebo, or dexmedetomidine
0.5 mcg/kg, 1 mcg/kg, or 2 mcg/kg. The researchers determined that a 2 mcg/kg bolus provided
superior block duration (p < 0.001) compared to the other groups.
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Lastly, Shin et al. (2018) conducted a randomized controlled trial in which 48 patients
undergoing total knee arthroplasty with spinal anesthesia were split equally into two groups. The
first group was given a 1 mcg/kg bolus of dexmedetomidine followed by an infusion of 0.1-0.5
mcg/kg/hr for intraoperative sedation. The second group was given continuous propofol infusion.
The dexmedetomidine sedation was associated with a small, but statistically significant
difference in 24 and 48-hour post-operative opioid consumption.
Postoperative Applications
Postoperatively, dexmedetomidine may be used in conjunction with narcotic analgesics
to decrease the total amount of narcotic received and improve analgesic effect and subjective
sleep quality. Li et al. (2018) conducted a pilot randomized controlled trial of 58 adults 60 years
of age or older after open abdominal surgery. These authors found that the primary outcome, 72hour morphine consumption, was significantly lower when morphine patient-controlled analgesia
was supplemented with dexmedetomidine versus morphine alone. The intervention group in this
study received morphine 0.5 mg/ml with dexmedetomidine 2 mcg/ml in normal saline 100 ml.
The patient-controlled analgesia was set to deliver a 2 ml bolus with an 8 minute lock-out period.
Pertinent secondary outcomes were measured in this group, and pain intensity was significantly
lower in the intervention group while sleep quality was significantly higher (Li et al., 2018).
The subject of this case study received no narcotic or other pain medication in PACU,
and only two doses of oxycodone-acetaminophen 5-325 within 24 hours after surgery. She also
had no significant post-operative hypotension or bradycardia. A Cochrane systematic review
conducted by Lundorf, Nedergaard, and Moller (2016) included seven studies with a total of 492
participants. Most of the studies found a decrease in rescue opioids within 24 hours after surgery,
but no significant decrease in postoperative pain. This is still significant, as it means that there
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has been a decrease in opioid consumption. The review also found an increased risk of postoperative hypotension with high-dose infusions, relatively low risk with lower dose infusions.
In addition to lowering perioperative narcotic requirements, postoperative nausea and
vomiting was shown to be less in patients receiving dexmedetomidine versus placebo. This
review stated the evidence to be very low to low due to the heterogeneity and potential bias of
the studies included. The authors of this review point out that additional studies of higher quality
should be done to determine the full scope of effect for perioperative dexmedetomidine.
Recommendations
Recommendation #1
To improve patient experience and pain management, anesthesia professionals should
administer preoperative membrane stabilizers (such as pregabalin or gabapentin), selective COX2 inhibitors (such as celecoxib or meloxicam), and acetaminophen when not contraindicated.
This recommendation is backed by several high-quality studies that show preoperative
administration of these medications can provide enhanced recovery after surgery.
Recommendation #2
Anesthesia professionals should consider using dexmedetomidine infusions in the
intraoperative period to enhance pain control, control the stress response to surgery, and assist in
sedation. Further studies are necessary to confirm its efficacy, but the initial evidence is showing
good results and better immediate postoperative pain control with the use of dexmedetomidine
infusions.
Intravenous dexmedetomidine bolus of 2 mcg/kg over 30 minutes after induction may
also have a role in prolonging the effects of peripheral and neuraxial anesthesia by increasing the
time until first pain at surgical site requiring rescue analgesia. These techniques should be used
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when prudent and possible to mitigate the use of intraoperative opioids and promote postoperative pain control. This recommendation is based on Grade A evidence showing that for as
long as the peripheral nerve block lasts, pain is well-controlled without opioids or with minimal
opioid administration. Use of peripheral regional anesthesia allows for up to 24 hours of
postoperative analgesia, depending on the local anesthetic agent used (Nagelhout & Elisha, 2018;
Kang et al., 2018).
Recommendation #3
Further research is needed to determine the true value of intraoperative and postoperative dexmedetomidine infusions for post-operative pain control. As ERAS protocols
become more commonly used, a randomized controlled study for protocols with and without
dexmedetomidine could be used. This would provide insight as to whether it is the other
components of ERAS (such as lidocaine, ketamine, and magnesium) that are providing for
improved pain management, or if dexmedetomidine itself has added benefit. Future research
should also look to determine whether dexmedetomidine should be bolused and infused at total,
ideal, or lean body weight, and whether there are specific effective dosing regimens for bolus
and infusion.
Conclusion
While there are many non-opioid methods of analgesia that may be employed by a
prudent anesthesia professional, the use of intraoperative infusion of dexmedetomidine should be
considered when a multimodal analgesic technique is utilized to decrease opioid use and improve
patient outcomes and satisfaction. This idea is consistent with the position statement made by the
American Association of Nurse Anesthetists (AANA) regarding the opioid crisis in America. It
is the responsibility of anesthesia professionals to collaborate with the interdisciplinary team to
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create comprehensive post-operative pain management strategies. In doing this, the
interdisciplinary team can decrease or eliminate the need for opioid pain medications throughout
the perioperative period (AANA, 2018).
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